AI assistant
NovoCure Ltd — Director's Dealing 2017
Feb 24, 2017
31949_dirs_2017-02-24_b84e77e4-6ee4-4f9f-965a-6775be7b1870.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Novocure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2017-02-22
Reporting Person: GROENHUYSEN WILHELMUS CM (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-22 | Options to Buy Ordinary Shares | $7.15 | A | 292500 | Acquired | 2027-02-22 | Ordinary Shares (292500) | Direct |
| 2017-02-22 | Restricted Stock Unit | $ | A | 130000 | Acquired | Ordinary Shares (130000) | Direct |
Footnotes
F1: Options to buy 292,500 ordinary shares will vest and become exercisable in equal installments on each of February 22, 2018, 2019, 2020 and 2021, subject to Mr. Groenhuysen's continued employment through such dates.
F2: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.
F3: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Groenhuysen's continued employment through such dates.